New technologies have always driven advances in clinical research, and that’s still true today. The Covid pandemic rapidly accelerated the adoption of decentralized trials, powered by emerging health tech, but in less dramatic times, life sciences must find ways to ensure continued innovation.

As an industry veteran and co-chair of the Digital Trials & Research Alliance (DTRA), Craig Lipset has a powerful perspective on the potential of emerging technologies, and how to successfully combat inertia and encourage adoption in clinical studies.

He joins Medidata CEO Anthony Costello to explore the origins of decentralized trials, the potential of Virtual Twins, and how the Buffalo Initiative is promoting research into understudied rare diseases.

Visi ...